Suppr超能文献

危重症患者中平衡晶体液与生理盐水的比较:一项荟萃分析的 PRISMA 研究。

Balanced crystalloids versus saline in critically ill patients: The PRISMA study of a meta-analysis.

机构信息

ICU Department, Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, Beijing, China.

Dongzhimen Hospital Affiliated to Beijing University of Traditional Chinese Medicine, Beijing, China.

出版信息

Medicine (Baltimore). 2021 Sep 24;100(38):e27203. doi: 10.1097/MD.0000000000027203.

Abstract

OBJECTIVE

To compare the safety of balanced crystalloids and saline among critically ill patients in intensive care unit (ICU).

METHODS

The Medline, EMBASE, Web of Science, Cochrane Library databases were systematically searched from the inception dates to May 17, 2020 in order to identify randomized controlled trials which evaluated the safety of balanced crystalloids and saline in critically ill patients. The primary outcome was major adverse kidney events within 30 days (MAKE30). The second outcomes included 30-day mortality, ICU mortality, In-hospital mortality, ICU length of stay, hospital length of stay, creatinine highest before discharge (mg/dl) and needs for renal replacement therapy (RRT).

RESULTS

A total of nine randomized controlled trials involving 19,578 critical ill patients fulfilled the inclusion criteria. The outcomes of this meta-analysis showed that balanced crystalloids treatment shared the same risk of MAKE30 with saline treatment among critical ill patients [RR = 0.95; 95%CI, 0.88 to 1.01; Z = 1.64 (P = .102)]. The clinical mortality which included 30-day mortality [RR = 0.92; 95%CI, 0.85 to 1.01; Z = 1.78 (P = .075)], ICU mortality [RR = 0.92; 95%CI, 0.83 to 1.02; Z = 1.67 (P = .094)] and In-hospital mortality [RR = 0.93; 95%CI, 0.71 to 1.21; Z = 0.55 (P = .585)] were similar between balanced crystalloids treatment and saline treatment among critical ill patients. Patients who received balanced crystalloids treatment or saline treatment needed the same length of ICU stay [WMD = 0.00; 95%CI, -0.09 to 0.10; Z = 0.09 (P = .932)] and hospital stay [WMD = 0.59; 95%CI, -0.33 to 1.51; Z = 1.26 (P = .209)]. Critical ill patients who received balanced crystalloids treatment or saline treatment had the same level of creatinine highest before discharge [WMD = 0.01; 95%CI, -0.02 to 0.04; Z = 0.76 (P = .446)] and needs for RRT [RR = 1.04; 95%CI, 0.75 to 1.43; Z = 0.21 (P = .830)]. Similar results were obtained in subgroups of trials stratified according to the age of patients (children or adults).

CONCLUSIONS

When compared with saline, balanced crystalloids could not reduce the risk of MAKE30, 30-day mortality, ICU mortality and in-hospital mortality, could not reduce the length of ICU stay, length of hospital stay, the level of creatinine highest before discharge and the needs for RRT among critical ill children and adults. Therefore, it was still too early for balanced crystalloids to replace normal saline among critical ill patients.

摘要

目的

比较重症监护病房(ICU)危重症患者中平衡晶体液和生理盐水的安全性。

方法

系统检索 Medline、EMBASE、Web of Science、Cochrane Library 数据库,检索时间从建库至 2020 年 5 月 17 日,以确定评估危重症患者中平衡晶体液和生理盐水安全性的随机对照试验。主要结局为 30 天内主要不良肾脏事件(MAKE30)。次要结局包括 30 天死亡率、ICU 死亡率、院内死亡率、ICU 住院时间、住院时间、出院前最高肌酐(mg/dl)和需要肾脏替代治疗(RRT)。

结果

共有 9 项随机对照试验纳入 19578 例危重症患者符合纳入标准。这项荟萃分析的结果表明,平衡晶体液治疗与生理盐水治疗在危重症患者中发生 MAKE30 的风险相同[RR=0.95;95%CI,0.88 至 1.01;Z=1.64(P=0.102)]。包括 30 天死亡率[RR=0.92;95%CI,0.85 至 1.01;Z=1.78(P=0.075)]、ICU 死亡率[RR=0.92;95%CI,0.83 至 1.02;Z=1.67(P=0.094)]和院内死亡率[RR=0.93;95%CI,0.71 至 1.21;Z=0.55(P=0.585)]在内的临床死亡率在接受平衡晶体液治疗和生理盐水治疗的危重症患者中相似。接受平衡晶体液治疗或生理盐水治疗的患者 ICU 住院时间[WMD=0.00;95%CI,-0.09 至 0.10;Z=0.09(P=0.932)]和住院时间[WMD=0.59;95%CI,-0.33 至 1.51;Z=1.26(P=0.209)]相同。接受平衡晶体液治疗或生理盐水治疗的危重症患者出院前最高肌酐水平[WMD=0.01;95%CI,-0.02 至 0.04;Z=0.76(P=0.446)]和需要 RRT[RR=1.04;95%CI,0.75 至 1.43;Z=0.21(P=0.830)]也相同。根据患者年龄(儿童或成人)进行亚组分析也得到了相似的结果。

结论

与生理盐水相比,平衡晶体液并不能降低危重症儿童和成人的 MAKE30、30 天死亡率、ICU 死亡率和院内死亡率的风险,也不能降低 ICU 住院时间、住院时间、出院前最高肌酐水平和 RRT 的需求。因此,在危重症患者中,平衡晶体液替代生理盐水还为时尚早。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/50f5/8462635/558291281f29/medi-100-e27203-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验